CORAMI

New treatment strategies for cardiac diseases

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels. We are focused on cardiac applications, leading with a therapeutic intervention for atrial fibrillation.

CorAmi Platform Technology

Platform device for targeted delivery of cardiac therapeutics has the potential to minimize the risk for off-target effects seen with systemic delivery

Proprietary therapeutic hydrogels designed to be positioned directly on the surface of the heart

Dr. Pamukcu was a Founder, Director and CSO of Cell Pathways, Inc.(CPI), an emerging pharmaceutical company acquired by OSI Pharmaceuticals. He directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing over the course of decade. He was also instrumental in obtaining over $140 million of capital and in the transformation of CPI to a public company. He received his B.A. in Biology from The Johns Hopkins University and his M.D. degree from the University of Wisconsin School of Medicine. Dr. Pamukcu has authored over 110 journal articles, book chapters, and abstracts and is an inventor on over 280 issued or pending patents in the areas of drug discovery and development for cancer prevention, cancer treatment, and inflammatory bowel disease.

Brian Walsh, MS MBA

Chief Operating Officer

Brian Walsh is a medical technology executive with over 30 years of medical technology experience. He has a history of successfully commercializing medical technologies in a variety of disciplines. Additionally, he has worked extensively with a variety of therapeutic technologies including Health IT. His experience spans a wide range of medical specialties including cardiology, orthopedics, surgery, and medical aesthetics. Most recently he was CEO for Dornier Medtech America, responsible for North and South America. He received his Bachelor and Master’s degrees in Bioengineering from the University of California, San Diego. He was awarded a Master’s of Business Administration from Emory Goizueta Business School in Atlanta, Georgia.

Rebecca Levit, MD

Chief Scientific Officer

Dr. Rebecca Levit is an Assistant Professor of Cardiology at Emory University in Atlanta, Georgia and adjunct faculty in the Department of Biomedical Engineering at the Georgia Institute of Technology. She completed her undergraduate training at Dickinson College in Carlisle, PA and medical school at The University of Pennsylvania School of Medicine in Philadelphia, PA. After medical school, Dr. Levit residency and fellowship training in cardiovascular disease at Emory University. She runs an active research lab funded by the American Heart Association. Her research focuses on translational stem cell therapies for heart disease. She also is the inventor of the CorAmi technology to deliver hydrogels to the heart. She has expertise in clinical cardiology, application of basic science research towards clinical applications, medical device start-ups, and pre-clinical animal models.